Back
Helmerich & Payne 10K Form
Buy
71
HP
Helmerich & Payne
Last Price:
41.63
Seasonality Move:
2.41%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2020-11-20 | 10K | HP/Helmerich & Payne Annual |
2020-07-29 | 10Q | HP/Helmerich & Payne Quarterly |
2020-05-04 | 10Q | HP/Helmerich & Payne Quarterly |
2020-02-05 | 10Q | HP/Helmerich & Payne Quarterly |
2019-11-15 | 10K | HP/Helmerich & Payne Annual |
2019-07-26 | 10Q | HP/Helmerich & Payne Quarterly |
Receive HP News And Ratings
See the #1 stock for the next 7 days that we like better than HP
HP Financial Statistics
Sales & Book Value
Annual Sales: | $2.06B |
---|---|
Cash Flow: | $192.44M |
Price / Cash Flow: | 11.65 |
Annual Sales: | $27.24 |
Price / Book: | 1.53 |
Profitability
EPS (TTM): | 3.81000 |
---|---|
Net Income (TTM): | $402.02M |
Gross Margin: | $224.55M |
Return on Equity: | 14.67% |
Return on Assets: | 9.22% |
Helmerich & Payne Earnings Forecast
Key Helmerich & Payne Financial Ratios
- The Gross Profit Margin over the past 39 years for HP is 10.91%.
- The Selling, General & Administrative Expenses for HP have been equal to 8.86% of Gross Profit Margin.
- The Research & Development expenses have been 1.29% of Revenue.
- The Interest Expense is 276.26% of Operating Income.
- The Net Earning history of HP is 0.34% of Total Revenues.
- Per Share Earnings over the last 39 years have been positive in 19 years.
Helmerich & Payne Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | S&P500 |
---|---|
Industry: | Oil & Gas Drilling |
Sector: | Energy |
Current Symbol: | HP |
CUSIP: | 423452 |
Website: | helmerichpayne.com |
Debt
Debt-to-Equity Ratio: | 0.2 |
---|---|
Current Ratio: | 2.29 |
Quick Ratio: | 1.71 |
Price-to-Earnings
Trailing P/E Ratio: | 832.4 |
---|---|
Forward P/E Ratio: | 11.48 |
HP Technical Analysis vs Fundamental Analysis
Buy
71
Helmerich & Payne (HP)
is a Buy
Is Helmerich & Payne a Buy or a Sell?
-
Helmerich & Payne stock is rated a Buy
The current Helmerich & Payne [HP] share price is $41.62. The Score for HP is 71, which is 42% above its historic median score of 50, and infers lower risk than normal.